17.10.2023 • NewsSyngentaagrochemicalsseed treatment

Syngenta Opens Biological Seed Treatment Center in Germany

Swiss-based and Chinese-owned agrochemicals company Syngenta has opened its first biologicals service center at the group’s Seedcare Institute in Maintal, Germany, addressing growing farmer demand across the EU for biological seed treatment solutions.

Syngenta currently operates 18 Seedcare Institutes with more than 120 experts globally. It said in statement that it plans to establish additional biological service centers to more Institutes in the future.

Biological seed treatment solutions ensure healthy crop establishment, by safeguarding plants from pests and improving their ability to access available nutrients. Only tiny amounts are necessary to coat the seed, helping increase soil health and protecting biodiversity and the environment. However, the incorporation of living organisms can present new challenges to developing biological seed treatment solutions, which will need to take into account factors such as biological compatibility and on-seed survivability, said Syngenta.

“Our leadership in biological innovation and seed treatment is built on our ability to constantly enhance and adapt our service offers,” said Jonathan Brown, global head of Syngenta’s Seedcare business unit. “This new biologicals service center enables the successful use of biologicals as seed-applied solutions through shared practical knowledge and resources. As the industry collaborator of choice, we look forward to launching new solutions together with our partners.”

© amenic181/Shutterstock
© amenic181/Shutterstock

According to Syngenta, the biologicals service center in Maintal offers specialized expertise to support the application of new biological seed treatments. These include competence in microbiology – from understanding the viability on-seed and in-mixture with other active ingredients, the ability to develop assays for all microbial products, to expertise on the handling of sensitive biologicals throughout the process. It can also provide advisory on water quality and recipe compatibility, on-seed survivability measurement, guidelines for storage, handling and cleaning, and specialized training on proper stewardship of biologicals.

Company

Syngenta International AG


Basel
Switzerland

Company contact







Interview

Specialty Chemicals in a Shifting World
Adapting to Tariffs and Strengthening Regional Networks

Specialty Chemicals in a Shifting World

Jennifer Abril, President & CEO of SOCMA, discusses the impact of new tariffs and the importance of regional supply networks in the specialty chemical industry.

Virtual Event

Digitalization in the Chemical Industry
CHEManager Spotlight

Digitalization in the Chemical Industry

Save the Date: October 22, 2025
The event will be promoted to a combined audience of over 100,000 professionals across Europe through the CHEManager and CITplus networks.

most read

Photo
19.03.2025 • News

Arkema Launches Acrylic Acid Purification Project

Arkema has announced the launch of its Carat Project at its Carling site in France. This initiative aims to enhance the capabilities and sustainability of the facility, which specializes in producing acrylic monomers and superabsorbent polymers.

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.

Photo
22.04.2025 • News

BASF Divests Two Joint Ventures in China

BASF has divested its shares in the joint venture companies, BASF Markor Chemical Manufacturing (Xinjiang) Co., Ltd. and Markor Meiou Chemical (Xinjiang) Co., Ltd. in Korla, China, to Verde Chemical Singapore Pte. Ltd.

Photo
13.03.2025 • News

Roche and Zealand Pharma Collaborate on Weight Management Drug

Swiss pharma heavyweight Roche announced has entered into an exclusive collaboration and licensing agreement with Denmark’s Zealand Pharma. Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog as a standalone therapy as well as a fixed-dose combination with Roche’s lead incretin asset CT-388.